Thierry Laugel

Co-Founder and Managing Partner at Kurma. Thierry co-founded Kurma Partners in 2009. He has 30 years of experience in Life Sciences, both in Venture and in Industry, and is a PharmD, PhD and MBA. Thierry started his career in 1992 as R&D Project Manager for Laboratoires Fournier in Tokyo. In 1996, he joined Flamel Technologies, just after its successful listing on Nasdaq, and managed the development-stage portfolio of the company. In 1998, he moved to investments, first at Caisse des Dépots (CDC), where he joined as Investment Manager and then Partner and oversaw a portfolio of 10 direct investments in France, Europe and US that generated a cash-on-cash return > 20% IRR (40 ME invested). In 2005, he joined AGF Private Equity (Allianz Group) in 2005 as Partner. The Investment volume was approx. Euro 15 million per year, and the cash-on-cash return was approx. 20% IRR (80 ME invested). In 2009, Thierry co-created Kurma Partners. The company has currently 700 ME of assets under Management, a team of 20 professionals in Paris and Munich, 6 funds under management in 3 verticals (Biopharma, digital health, and growth), and a portfolio of approx. 50 companies. Since 2021, Eurazeo is the majority shareholder of Kurma Partners. He is currently a Board Member at Vivet Therapeutics, Amolyt Pharma, Ermium, Coave Therapeutics, Blink Biomedical, Pathoquest, Corteria (Chairman),and Argobio Studio (Chairman).